Very high levels of soluble CD30 recognize the patients with classical Hodgkin's lymphoma retaining a very poor prognosis-Reference-Cited by-同舟云学术

Very high levels of soluble CD30 recognize the patients with classical Hodgkin's lymphoma retaining a very poor prognosis

Published:2006-11 Issue:5 Volume:77 Page:387-394
ISSN:0902-4441
Container-title:European Journal of Haematology
language:en
Short-container-title:Eur J Haematol

Author:

Visco Carlo,Nadali Gianpaolo,Vassilakopoulos Theodoros P.,Bonfante Valeria,Viviani Simonetta,Gianni Alessandro M.,Federico Massimo,Luminari Stefano,Peethambaram Prema,Witzig Thomas E.,Pangalis Gerassimos,Cabanillas Fernando,Medeiros L. Jeffrey,Sarris Andreas H.,Pizzolo Giovanni

Publisher

Wiley

Subject

Hematology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1600-0609.2006.00725.x/fullpdf

Reference36 articles.

1. CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy

2. CD30 Is Involved in Inhibition of T-Cell Proliferation by Hodgkin’s Reed-Sternberg Cells 1

3. Ki-1 (CD30) antigen is released by Ki-1-positive tumor cellsin vitro andin vivo. I. Partial characterization of soluble Ki-1 antigen and detection of the antigen in cell culture supernatants and in serum by an enzyme-linked immunosorbent assay

4. Increased serum levels of soluble IL-2 receptor, CD30 and CD8 molecules, and gamma-interferon in angioimmunoblastic lymphadenopathy: possible pathogenetic role of immunoactivation mechanisms

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Protein Cancer Biomarkers;Current Cancer Biomarkers;2023-01

2. Results of a UK National Cancer Research Institute Phase II study of brentuximab vedotin using a response‐adapted design in the first‐line treatment of patients with classical Hodgkin lymphoma unsuitable for chemotherapy due to age, frailty or comorbidity (BREVITY);British Journal of Haematology;2020-09-14

3. Immunotherapy in Hodgkin Lymphoma: Present Status and Future Strategies;Cancers;2019-07-29

4. A phase 2 study of brentuximab vedotin in patients with CD30-positive advanced systemic mastocytosis;Blood Advances;2019-07-26

5. Plasma Factors for the Differentiation of Hodgkin’s Lymphoma and Diffused Large B Cell Lymphoma and for Monitoring Remission;Journal of Hematology;2019